Related Experiment Videos
Modulation of oligonucleotide duplex and triplex stability via hydrophobic interactions
1Lynx Therapeutics, Inc., Foster City, CA 94404.
Nucleic Acids Research
|December 25, 1993
Summary
Cholesterol-conjugated synthetic oligonucleotides show enhanced binding to target nucleic acids. These modified DNA and RNA molecules demonstrate increased stability and specificity, paving the way for advanced pharmaceutical applications.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Molecular Biology
Background:
- Synthetic oligonucleotides are a novel class of pharmaceuticals.
- Their mechanism involves Watson-Crick or Hoogsteen base pairing with target nucleic acids.
- Cholesterol conjugation is explored to enhance oligonucleotide properties.
Purpose of the Study:
- To synthesize and evaluate cholesterol-conjugated oligonucleotides.
- To investigate the impact of cholesterol conjugation on duplex and triplex stability.
- To assess the specificity and mismatch discrimination of these modified oligonucleotides.
Main Methods:
- Synthesis of 3'-cholesterol and/or 5'-cholesterol conjugated oligonucleotides.
- Formation of tandemly addressed duplexes and clamp-shaped triplexes.
- Measurement of duplex and triplex melting temperatures (Tm) to assess stability.
- Evaluation of mismatch discrimination using various oligonucleotide constructs.
Main Results:
- Duplexes formed by tandem oligonucleotides showed increased Tm up to 13.3°C.
- Cholesterol conjugates exhibited improved mismatch discrimination compared to unmodified oligomers.
- 5',3'-bis-cholesterol oligomers formed stable triple-stranded complexes with Tm stabilization up to 30°C.
- No triplex formation was detected with mismatched targets.
Conclusions:
- Hydrophobic interactions between cholesterol moieties significantly stabilize nucleic acid complexes.
- Cholesterol conjugation enhances both the stability and specificity of synthetic oligonucleotides.
- These findings support the potential of cholesterol-conjugated oligonucleotides as therapeutic agents.